In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klunemann, T., Araujo Cruz, M.M., Kloos, A., Goerlich, K., Schottmann, R., Othman, B., Struys, E.A., Bahre, H., Grote-Koska, D., Brand, K., Ganser, A., Preller, M., Heuser, M.(2020) Leukemia 34: 416-426
- PubMed: 31586149 
- DOI: 10.1038/s41375-019-0582-x
- Primary Citation of Related Structures:  
6Q6F - PubMed Abstract: 
Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients. Mutant IDH produces R-2-hydroxyglutarate (R-2HG), which induces histone- and DNA-hypermethylation through the inhibition of epigenetic regulators, thus linking metabolism to tumorigenesis ...